About This Tool

The Libtayo (cemiplimab) Dosing & Scheduling Tool calculator is designed for healthcare professionals to quickly determine the administration schedule for patients based on the standard FDA-approved regimen. It simplifies planning by projecting future infusion dates from the last known dose, supporting adherence to the prescribed treatment timeline.

Outputs

After entering the required information, the calculator provides a clear summary of the patient’s dosing schedule, including:

• Recommended Dose: The standard fixed dose of 350 mg.
• Dosing Frequency: The standard every 3 weeks (Q3W) interval.
• Next Scheduled Infusion: The exact date for the next administration.
• Upcoming Schedule: A preview of the subsequent three infusion dates to aid in long-term planning.

How to Use

To calculate a patient’s Libtayo schedule, follow these simple steps:

• Select Indication: Choose the relevant FDA-approved indication from the dropdown menu (e.g., CSCC, BCC, NSCLC, Cervical Cancer).
• Enter Last Administration Date: Use the date picker to input the date of the most recent or current Libtayo infusion.
• Calculate: Click the “Calculate Schedule” button to generate the results. The tool will instantly display the next scheduled dose and future dates.

Dosing Overview

The recommended dosage of Libtayo for all approved indications is a fixed dose of 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks. Treatment should continue until disease progression or unacceptable toxicity occurs. No dose adjustments are recommended based on body weight. Administration should always be performed by a qualified healthcare professional.

Switching

There is no specific guidance in the Prescribing Information regarding a washout period when switching to Libtayo from other systemic therapies. The decision to initiate Libtayo should be based on clinical judgment, considering the half-life and potential for overlapping toxicities of the previous agent. Consultation with the full Prescribing Information and relevant clinical guidelines is essential.

Missed Dose

According to the official Prescribing Information, if a planned dose of Libtayo is missed, it should be administered as soon as possible. The administration schedule should then be adjusted to maintain the 3-week interval between doses. This tool can be used to recalculate the new schedule by entering the date the missed dose was actually administered.

Safety Alerts

Libtayo is an immune checkpoint inhibitor and can cause severe or fatal immune-mediated adverse reactions. It is critical to monitor patients for these reactions and manage them promptly. The following table provides a simplified summary of dose modifications for common adverse reactions. Always consult the full Prescribing Information for complete guidance.

Frequently Asked Questions (FAQ)

What dosing regimen does this calculator use?

The calculator is based exclusively on the FDA-approved standard dosing regimen for Libtayo, which is 350 mg administered intravenously every 3 weeks (Q3W).

Does the tool calculate dosing for pediatric patients?

No. The safety and effectiveness of Libtayo have not been established in pediatric patients. This tool should only be used for adult patients as per the approved indications.

Can the calculator adjust for dose interruptions or modifications?

The tool does not calculate dose reductions, as none are recommended. To handle a dose delay, simply enter the new date of administration to recalculate the subsequent schedule based on the standard 3-week interval.

Does patient weight affect the dose calculated by the tool?

No. Libtayo is administered as a fixed 350 mg dose and is not weight-based. The tool reflects this fixed-dosing strategy.

Which indications are covered by the tool?

The calculator includes all major FDA-approved indications for Libtayo monotherapy: Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC), Non-Small Cell Lung Cancer (NSCLC), and Cervical Cancer.

How long is the infusion time for Libtayo?

The standard infusion time is 30 minutes. This calculator focuses on the dosing schedule and does not track infusion duration.

What happens if I enter a date in the distant future or past?

The tool will calculate a schedule based on any valid date entered. It is the user’s responsibility to input a clinically relevant date corresponding to the last or current administration to ensure the output is meaningful for patient planning.

Is this tool a substitute for the official Prescribing Information?

Absolutely not. This tool is for informational and planning purposes only and must not replace clinical judgment or the official FDA-approved Prescribing Information, which should always be consulted as the primary source of truth.

References

1. Libtayo (cemiplimab-rwlc) Prescribing Information. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. View PDF
2. LIBTAYO® (cemiplimab-rwlc) Official Healthcare Professional Website. Regeneron and Sanofi. Visit website
3. National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology. View guidelines
4. U.S. Food and Drug Administration. Drugs@FDA Database: Libtayo (cemiplimab). Visit database